What Kestra Medical Technologies, Inc. does

Kestra Medical Technologies, Inc. is a publicly traded medical device company (NASDAQ: KMTS) founded in 2014 and headquartered in Kirkland, Washington, that develops and commercializes the ASSURE Wearable Cardioverter Defibrillator (WCD) system for patients at elevated risk of sudden cardiac arrest (SCA). The platform serves heart failure patients, post-myocardial infarction patients, and individuals with low left ventricular ejection fraction (LVEF ≤35%) who are awaiting eligibility for or refusing an implantable cardioverter defibrillator (ICD). The integrated Cardiac Recovery System combines the SensorFit Garment (a breathable, non-adhesive wearable with embedded ECG sensors), the ASSURE Monitor, the proprietary ASSURE Detection Algorithm with Quad Channel Processing and Adaptive Patient Intelligence, the Kestra CareStation cloud-based remote patient data platform, and the ASSURE Patient App.

The underlying technology centers on a four-channel ECG analysis pipeline that determines heart rate and rhythm while filtering motion artifacts to minimize false positives, paired with an autonomous defibrillation delivery mechanism. Clinical performance has been validated in the ACE-PAS post-approval study (enrollment exceeding 20,000 patients), demonstrating 100% VT/VF shock conversion success, >95% first shock success, >23 hours/day median wear time, and 94% freedom from false positive shock alarms versus 54% for competing WCDs. The company generates revenue primarily through the sale and rental of the ASSURE WCD system initiated via physician prescription, with reimbursement flowing through insurance and healthcare payer contracts that now cover over 70% of payer mix.

Kestra sells exclusively in the United States through a direct field sales force of approximately 130 representatives covering 130 territories, targeting cardiologists, electrophysiologists, and hospital cardiac units. An online prescriber portal supports physician registration, and Kestra-trained patient service representatives conduct device fitting and training. Following its $202 million IPO in mid-2025 and a $138 million follow-on offering in December 2025, the company has aggressively scaled commercial operations, with prescription volumes up 58% year-over-year and Q3 FY2026 revenue of $24.6 million (63% YoY growth). The company remains unprofitable — Q3 FY2026 net loss of $34.2 million — and has signaled expansion into cuffless blood pressure monitoring through a January 2026 strategic collaboration with Biobeat Technologies.

Name

Kestra Medical Technologies, Inc.

Legal name

Kestra Medical Technologies, Inc.

Website

https://kestramedical.com

Company type

Public

Founded year

2014

Operating status

Operating

Headcount range

101–250 employees

Short description

Kestra Medical Technologies (NASDAQ: KMTS) is a publicly traded U.S. medical device company that develops and commercializes the ASSURE Wearable Cardioverter Defibrillator system, providing continuous cardiac monitoring and autonomous defibrillation therapy to at-risk cardiac patients through physician prescriptions and a 130-rep U.S. field sales force.

Ownership category

akta.pro rank

Product category

Wearable Medical Devices

NAICS

Electromedical and Electrotherapeutic Apparatus Manufacturing (334510), Navigational, Measuring, Electromedical, and Control Instruments Manufacturing (33451)

SIC

Electromedical & Electrotherapeutic Apparatus (3845), Surgical & Medical Instruments & Apparatus (3841)

akta.pro primary industry

Cardiac Rhythm Management (Pacemakers, ICDs, CRT) (HLAHAFAC)

akta.pro secondary industries

Cardiac Monitoring (ECG/Holter/Event/Patch, Loop Recorders) (HLAHACAB), Cardiac Assist & Heart Failure Therapies (Implantables, Neuromodulation) (HLAHAFAL), Clinical-Grade Vital Signs Monitoring (ECG, SpO2, BP, Temp, Respiration) (HLACAPAI), Cardiometabolic RPM & Chronic Disease Management (diabetes, hypertension, CHF, obesity) (HLALAFAA)

Keywords

• Wearable defibrillators
• Cardiac monitoring devices
• Sudden cardiac arrest
• Medical wearables
• Remote cardiac monitoring

Headquarters

HQ city

Kirkland

HQ country

United States

HQ region

North America

Offices2 records

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Personnel, Operations, Marketing or Sales, Technology or R&D, Supply Chain, Infrastructure

Revenue model

1. ASSURE WCD System (Hardware + Service): The company generates revenue primarily through the sale and rental of the ASSURE Wearable Cardioverter Defibrillator system, which includes the SensorFit Garment, ASSURE Monitor, and associated services (Kestra CareStation platform, ASSURE Patient App, ASSURE Assist Service). Revenue is driven by prescription volume, revenue per fit, and improved payer mix with over 70% of payer mix covered by payer contracts. Q3 FY2026 revenue of $24.6 million with 63% year-over-year growth.
2. ASSURE Wearable ECG (Non-Therapeutic Monitoring): Non-therapeutic wearable ECG continuation monitoring for patients who have completed WCD use, generating additional revenue per prescription through the same platform infrastructure.

Pricing tiers

Go-to-market motion2 records

Distribution channels4 records

Marketing channels7 records

Core offering

Kestra Medical Technologies develops and commercializes the ASSURE Wearable Cardioverter Defibrillator (WCD) system — an FDA-approved wearable medical device that continuously monitors heart rhythm, autonomously detects ventricular arrhythmias (VT/VF), and delivers automatic defibrillation therapy to patients at elevated risk of sudden cardiac arrest. The integrated Cardiac Recovery System combines the ASSURE Monitor, SensorFit Garment with embedded ECG sensors, ASSURE Patient App, and the Kestra CareStation remote patient data platform, sold through physician prescription and insurance/payer reimbursement to cardiologists, electrophysiologists, and hospital systems.

Product overview

Kestra Medical Technologies offers a unified Cardiac Recovery System platform centered on the ASSURE Wearable Cardioverter Defibrillator (WCD), which provides autonomous detection and defibrillation for patients at risk of sudden cardiac arrest. The platform comprises the ASSURE WCD (the core therapeutic device), the ASSURE Wearable ECG (a non-therapeutic monitoring continuation), the ASSURE Patient App (for patient data transmission and self-management), the Kestra CareStation remote patient data platform (for clinical monitoring), SensorFit Garments (the wearable sensing component), the HeartPoint Alert Button (patient interaction interface), and ASSURE Assist Service (emergency response support). These components work together to deliver continuous cardiac monitoring, automatic arrhythmia detection, and coordinated care management during cardiac recovery.

Differentiator

Problem solved

Functional benefit

Brands

• ASSURE WCD: Wearable Cardioverter Defibrillator system for patients at risk of sudden cardiac arrest
• ASSURE Wearable ECG
• Kestra CareStation
• ASSURE Patient App
• ASSURE Assist Service
• SensorFit Garments
• HeartPoint Alert Button
• Cardiac Recovery System
• Empathy Powered Design

Products and services

• ASSURE Wearable Cardioverter Defibrillator (WCD) System

Quantifiable outcome

• 94% of ASSURE WCD patients never experience a false positive shock alarm (vs 54% for other WCD devices) based on ACE-PAS study (n=5,929)
• +5 more outcomes

Named customers3 records

Segments3 records

Ideal customer profiles2 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Integration2 records

AI capability3 records

Feature9 records

Partnerships

Two partnerships are on record, tiered core and minor.

• Biobeat TechnologiescoreStrategic or Co-development Partner · 13 January 2026Strategic collaboration to integrate cuffless blood pressure monitoring technology into the ASSURE Wearable Cardioverter Defibrillator system. The partnership includes an exclusive license and co-development arrangement. Kestra made a $5 million equity investment in Biobeat's Series B financing round. The collaboration addresses clinical findings from Kestra's Post-Approval Study showing 72% of WCD patients are hypertensive, aiming to enhance diagnostic insight and clinical decision-making during cardiac recovery.
• MedAxiomminorStrategic or Co-development PartnerMedAxiom hosted an on-demand panel discussion reviewing the ACE-PAS study's design and outcomes with leading investigators and clinical experts, exploring how the trial may inform care decisions for patients at elevated SCA risk.

Scale indicators17 records

Recent moves8 records

Expansion highlights6 records

Direct peers

• ZOLL Medical Corporation (LifeVest): ZOLL's LifeVest is the dominant wearable cardioverter defibrillator and the direct competitor to Kestra's ASSURE WCD, serving the same at-risk cardiac patient population with similar prescription-driven economics and payer reimbursement model.

Broad incumbents

• Philips (HeartStart): Philips is a broad incumbent in cardiac care with defibrillation and patient monitoring portfolios, including external AED products that overlap with the wearable defibrillator category Kestra operates in.
• Medtronic: Medtronic is the global leader in implantable ICDs and CRTs, addressing the same sudden cardiac arrest risk population Kestra serves but with chronic implantable therapies rather than wearable bridge devices.
• Boston Scientific: Boston Scientific is a major manufacturer of ICDs and cardiac rhythm management devices, competing for the same electrophysiology prescribing relationships that drive WCD adoption decisions.
• Abbott: Abbott manufactures implantable defibrillators and cardiac monitoring products through its Cardiovascular segment, addressing the same at-risk patient pool with permanent ICD therapies.

Emerging players

• iRhythm Technologies: iRhythm's Zio wearable ECG patch focuses on ambulatory cardiac rhythm monitoring, a directly adjacent technology category to the ASSURE Wearable ECG non-therapeutic monitoring product.
• Eko Health: Eko develops AI-enabled digital stethoscopes and cardiac monitoring tools, operating in the same digital cardiology space as Kestra CareStation with a focus on AI-driven arrhythmia detection.
• Cardiac Insight (now part of iCardiac): Cardiac Insight's Cardea SOLO wearable ECG sensor competes in the ambulatory cardiac monitoring space, overlapping with Kestra's non-therapeutic ASSURE Wearable ECG continuation product.
• HeartBeam: HeartBeam is an emerging digital health company developing a 3D ECG device for ambulatory cardiac monitoring, operating in a similar ambulatory cardiac diagnostics category as Kestra's CareStation platform.

Others

• Biobeat Technologies: Biobeat is Kestra's strategic partner for cuffless blood pressure monitoring integration into the ASSURE WCD, and a related wearable vital-signs platform that is being co-developed with Kestra's Cardiac Recovery System.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

• LinkedInlinkedin.com/company/kestra-medical-technologies

Compliance3 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles21 records

Funding overview

Funding rounds4 records

Investors12 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Kestra Medical Technologies, Inc.